Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bouteloua gracilis pollen is the allergenic pollen derived from the Bouteloua gracilis plant, commonly known as blue grama. It is primarily used in allergenic testing and immunotherapy for individuals with grass pollen allergies. The mechanism of action involves provoking an immune response in sensitized individuals, which can be harnessed diagnostically or therapeutically to desensitize patients to grass pollens. Blue grama is a warm-season perennial grass native to North America and produces moderate levels of allergenic pollen during its flowering season[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bouteloua gracilis pollen.